Market Overview

Deutsche Bank Raises Regeneron's Price Target To $425


Regeneron (NASDAQ: REGN) moved higher on the Tuesday session to top at $337 from the $313 open. The stock faded towards the later part of the session.

In a mid-day note on Tuesday, Deutsche Bank reiterates its buy rating, and raised their price target from $410 to $425.

Deutsche Bank mentions the solid earnings results and the beat on expectations for Regeneron's highest grossing drug, Eylea:

“Eylea 2Q sales in the US were $415M vs. $410M consensus. In 1Q'14 the company did $359M in Eylea Us sales. Since 1Q'14 sales were impacted by weather and inventory this growth was expected in 2Q. The co reaffirmed 2014 full year guidance at $1.7-$1.8B. We note that this guidance means ~$925-$1025M sales in 2H'14 vs. ~$775M sales in 1H'14. Per our calc this suggests ~$50-$150M incremental sales in DME in 2H'14.”

Latest Ratings for REGN

Mar 2020Argus ResearchMaintainsBuy
Mar 2020OppenheimerMaintainsOutperform
Mar 2020CFRADowngradesBuyHold

View More Analyst Ratings for REGN
View the Latest Analyst Ratings


Related Articles (REGN)

View Comments and Join the Discussion!

Posted-In: Deutsche BankAnalyst Color Price Target Reiteration Analyst Ratings

Latest Ratings

SAICSunTrust Robinson HumphreyMaintains95.0
GPNSunTrust Robinson HumphreyMaintains165.0
FISVSunTrust Robinson HumphreyMaintains110.0
FISSunTrust Robinson HumphreyUpgrades140.0
WUNorthland SecuritiesMaintains15.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at